Anti Cd 20 Ocrevus denied as not medically necessary by Blue Cross Blue Shield?
Most insurers reverse a medical-necessity denial when the appeal cites the specific clinical guideline (NCCN, ADA, AACE, etc.) that supports the requested treatment for your indication.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Blue Cross Blue Shield typically requires
Blue Cross Blue Shield's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Blue Cross Blue Shield angle on Anti Cd 20 Ocrevus
## Why BCBS Denies Ocrelizumab on Medical-Necessity Grounds
Blue Cross Blue Shield plans frequently issue medical-necessity denials for ocrelizumab (Ocrevus) when the submitted documentation does not clearly demonstrate that the patient's diagnosis, disease course, and prior treatment history align with the criteria set out in BCBS's own published coverage policy and in the FDA-approved prescribing label. Reviewers look for specific chart evidence — not just a diagnosis code — confirming the form and severity of multiple sclerosis, the inadequacy or intolerance of prior therapies, and the prescriber's individualized clinical rationale.
## Why This Denial Is Appealable
A medical-necessity denial is a coverage determination, not a final answer. Under the ACA (§2719) and ERISA (§503), you have the right to a full-and-fair internal appeal and, if that is upheld, an independent external review by a certified Independent Review Organization (IRO). The external-review window is typically around four months from the date of the adverse determination; check your Summary Plan Description for the exact deadline. An expedited (72-hour) review is available when the standard timeline would seriously jeopardize health.
## Your Appeal Timeline
1. Request the denial letter and the plan's coverage policy — both must be provided on request. 2. File the internal appeal — usually within 180 days of the denial; confirm your plan's deadline. 3. Await the internal decision — plans must respond within regulatory timeframes (30 days for pre-service, 60 days for post-service). 4. Escalate to external review if the internal appeal is denied — file promptly to stay within the four-month window.
## Documentation to Gather
- Confirmed diagnosis records: neurology notes, MRI reports, and any clinical findings that establish the specific MS diagnosis and its course (relapsing or primary progressive).
- Prior-treatment history: names of all previously tried disease-modifying therapies, start and stop dates, documented outcomes, and reasons for discontinuation (inadequate response, intolerance, or contraindication).
- Clinical severity evidence: recent MRI findings, EDSS or equivalent functional scores from the chart, and relapse documentation with dates.
- Prescriber medical-necessity letter: a detailed letter from the treating neurologist explaining why ocrelizumab is the appropriate next step for this specific patient, referencing the applicable guideline organization (such as the relevant AAN guideline) without relying on population statistics.
- Peer-reviewed support: published literature from recognized neurology societies supporting the use of anti-CD20 therapy in the patient's MS subtype.
## Criteria-Mapping Structure
Obtain the two controlling documents: (1) the FDA-approved prescribing information for ocrelizumab and (2) BCBS's current published medical policy for ocrelizumab or anti-CD20 therapies for MS. For each requirement listed in those documents, create a side-by-side table:
| Policy / Label Requirement | Chart Evidence That Satisfies It | Source Document & Date | |---|---|---| | Confirmed MS subtype | Neurologist diagnosis note | [Date] | | Prior therapy trial(s) | Treatment summary with outcomes | [Date range] | | Clinical severity indicator | MRI / functional score from chart | [Date] |
Submit this mapping with your appeal so the reviewer cannot overlook how each criterion is met. A well-organized, criterion-by-criterion response is the single most effective way to overturn a medical-necessity denial.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →Related appeal guides
- Blue Cross Blue Shield denied as not medically necessary of 17ohp Compounded
- Blue Cross Blue Shield denied as not medically necessary of AAT Augmentation
- Blue Cross Blue Shield denied as not medically necessary of Amphetamine Stimulant Prodrug
- Blue Cross Blue Shield denied as not medically necessary of Arni Entresto